Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
- 1 September 2004
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (3) , 685-692
- https://doi.org/10.1016/j.ygyno.2004.06.018
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Reactivating the expression of methylation silenced genes in human cancerOncogene, 2002
- Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancerInternational Journal of Cancer, 2002
- Loss of Expression of the p16 Tumor Suppressor Gene Is More Frequent in Advanced Ovarian Cancers Lacking p53 MutationsGynecologic Oncology, 2001
- p16(MTS-1/CDKN2/INK4a) in Cancer ProgressionExperimental Cell Research, 2001
- Inverse Expression of Cdk4 and p16 in Epithelial Ovarian TumorsGynecologic Oncology, 2000
- The INK4a/ARF locus in murine tumorigenesisCarcinogenesis: Integrative Cancer Research, 2000
- DNA MethylationBlood, 1999
- Role of the p16 tumor suppressor gene in cancer.Journal of Clinical Oncology, 1998
- Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumoursBritish Journal of Cancer, 1997
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993